Article
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Cancer - 1 Sept 2004
Albitar Maher, Do Kim-Anh, Johnson Marcella M, Giles Francis J, Jilani Iman, O'Brien Susan, Cortes Jorge, Thomas Deborah, Rassenti Laura Z, Kipps Thomas J, Kantarjian Hagop M, Keating Michael
Abstract excerpt
BACKGROUND: The CD52 antigen is a glycoprotein anchored on the cell membrane of mature B and T lymphocytes, monocytes, and eosinophils. Alemtuzumab (CAMPATH-1H; anti-CD52) is currently approved for the treatment of patients with refractory chronic lymphocytic leukemia (CLL). The authors investiga...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.